继前不久的“药瓶内涉嫌含玻璃碎屑”事件后，科伦药业再遭打击。该公司4日发布公告称，因在2011年使用4.26亿元超募资金收购君健塑胶过程中未披露双方关联关系，科伦药业收到了来自四川省证监局的处罚决定。

    Following the recent"Suspected of containing glass debris inside the bottle"After the event,Koren pharmaceutical another blow.The company 4 announcement said,By using 426 million yuan in 2011 to raise funds in the process of acquisition of jun jian plastic undisclosed relationship on both sides,Koren pharmaceutical received from sichuan province securities regulatory bureau of the penalty decision.

    根据公告，包括董事长刘革新、副总经理潘慧在内的6名高管以及张胜等两名保荐代表人，受到了四川省证监局的警示。

    According to the announcement,Including chairman liu's innovation/Pan Hui, deputy general manager of six executives and Zhang Sheng two sponsor representative,Warnings by sichuan province securities regulatory bureau.

    关联交易被隐瞒两年  Related party transactions concealment for two years

    公告透露，科伦药业于5月3日收到四川证监局下发的《关于对科伦药业采取责令改正措施的决定》等3份处罚文件。

    Announcements revealed,Koren pharmaceutical received on May 3rd. Sichuan province securities regulatory bureau issued by[About koren pharmaceutical measures shall be ordered to correct decision]Etc. 3 punishment according to the documents.

    科伦药业遭受处罚祸起一桩交易中的信息披露问题。2011年，科伦药业使用4.26亿元的超募资金收购了崇州君健塑胶有限公司100%股权。审计显示，截至2010年底，成立2年的君健塑胶总资产为1.87亿元，净资产0.83亿元。

    Koren pharmaceutical industry suffered a punishment for a deal, the problem of information disclosure.In 2011,,Koren pharmaceutical use 426 million yuan of funds raised in excess of the acquired chung state jun jian plastic co., LTD. 100% stake.The audit showed,By the end of 2010,Founded 2 years kin plastic the prince of the total assets of 187 million yuan,Net worth of $083 million.

    君健塑胶主营医用塑料组合盖，科伦药业为国内大输液行业的龙头企业，二者存在紧密的业务关系。数据显示，2009年10月至2011年3月间，君健塑胶对科伦药业累计销售额为3.13亿元，科伦药业几乎是其唯一的客户。

    Jun jian plastic main medical plastic combination cover,Koren pharmaceutical industry for the domestic large infusion of industry leading enterprises,There is a close business relationship.According to data,In October 2009 to March 2011,Jun jian plastic for koren pharmaceutical accumulative total sales of 313 million yuan,Koren pharmaceutical is almost the only customer.

    此次交易当时曾引发部分投资者对科伦药业涉嫌利益输送的怀疑。2009年，一份源自崇州官方的新闻稿称，君健塑胶由四川科伦实业集团（以下简称“科伦实业”）投资4亿元建立。

    The deal had caused some investors to koren pharmaceutical doubt for the indemnification.In 2009,,A press release from chung chi state official said,Jun jian plastic by koren industrial group in sichuan province(Hereinafter referred to as the"Koren industrial")Investment of 400 million yuan.

    但科伦药业在收购公告中和此后面对投资者质疑时声称，科伦药业与君健塑胶之间不存在关联交易。

    但科伦药业在收购公告中和Since then面对投资者质疑时声称,Koren pharmaceutical and jun jian plastic does not exist between related party transactions.

    如今，双方交易已完成两年，其间关联性因四川证监局的处罚得以示人。根据公告，君健塑胶实际出资人是四川惠丰投资发展有限责任公司，而后者的实际出资人是科伦药业和科伦实业的员工。

    now,The transaction has been completed for two years,Meantime correlation in sichuan province securities regulatory bureau punishment.According to the announcement,Jun jian plastic actual investor is sichuan HuiFeng investment development co., LTD,While the latter is the actual investor koren pharmaceutical and koren industrial employees.

    一笔40亿投资遭质疑   A 4 billion investment has been questioned

    监管部门认定，此次收购中，科伦药业未能真实、准确、完整披露交易对方的情况及交易双方之间的关联关系，违反了《上市公司信息披露管理办法》有关规定。

    Regulators decided that,The acquisition of,Koren pharmaceutical failed to true/accurate/Full disclosure of the trading relationship between each other's situation and trading,A violation of the[On the市公司信息披露管理办法]The relevant provisions of the.

    除要求限期制定整改措施外，四川省证监局对科伦药业董事长刘革新、副总经理潘慧、董秘熊鹰等6名高管提出警示。

    In addition to the requirements to formulate corrective measures within a time limit,Sichuan province securities regulatory bureau to innovate koren pharmaceutical chairman liu/Deputy general manager Pan Hui/Chairman secretary Xiong Ying six executives warn.

    时任保荐代表人的张胜、隋英鹏也因未能尽责履行督导业务，也被警示。二者供职于国金证券。

    Then the Zhang Sheng sponsor representative/SuiYingPeng is also responsible for failing to perform the supervision business,Have also been warning.Both serve Yu Guojin securities.

    此份处罚发布后，有投资者发帖称，对科伦药业的诚信感到失望。该投资者认为，除隐瞒了上述关联交易外，科伦药业至今未对总投资40亿元的伊犁川宁“药谷”项目中的2位自然人股东身份作出说明。

    This punishment after the release,There are investors post said,Am disappointed with koren pharmaceutical industry credibility.The investors said,除隐瞒了On the述关联交易外,Koren pharmaceutical yet ili chuan ning for a total investment of 4 billion yuan"Medicine valley"Explain the two natural person shareholder status in the project.

    ■ 背景  S background

    科伦药业陷“碎屑风波”     Koren pharmaceutical in"Elastic wave"

    此次因信披问题招罚，已是科伦药业近期内第二次陷入舆论漩涡。

    The faith problem for penalty,已是科伦药业近期内In the second次陷入舆论漩涡.

    4月26日，新华社刊文称，四川一家上市公司所生产的碳酸氢钠注射液存在包装缺陷。这种以钠钙玻璃瓶装的注射液，会在出厂3个月后，与碳酸氢钠药液发生反应产生碎屑颗粒。

    In April26日,According to xinhua news agency,四川一家On the市公司所生产的碳酸氢钠注射液存在包装缺陷.In the soda lime glass bottled water injection,Will be in the factory after 3 months,Clastic particles react with sodium bicarbonate solution.

    该文称，碎屑可随药品直接注入血管，易导致毛细血管堵塞、肉芽肿等，重者碎屑会嵌入脑部血管，危及生命。

    In this paper, according to,Debris with the drug directly into the blood vessels,Easy to cause the clogging in the capillaries/Granulation is swollen, etc.,The person that weigh debris will be embedded in the brain blood vessels,life-threatening.

    后来，多家媒体指认，此文所涉及的上市公司系科伦药业。

    later,Identify several media,此文所涉及的On the市公司系科伦药业.

    科伦药业于5月2日发布澄清公告称，暂时无法确定文中药品为其生产，其目前正在进行包装相容性研究，并通过研究发现，“采用钠钙玻璃输液瓶包装的碳酸氢钠注射液，在考察期内质量稳定，各项指标符合要求”。

    Koren pharmaceutical clarification announcement released on May 2,Temporarily unable to determine the drug for its production,The ongoing packaging compatibility studies,And through the study found,"Using soda lime glass infusion bottle packaging of sodium bicarbonate injection,During the study period with stable quality,The indicators meet the requirements".

    科伦药业副总葛均友也以两度接受媒体采访的形式，强调钠钙玻璃瓶装碳酸氢钠注射液的安全性。（尹聪）

    Koren pharmaceutical vice President ge friends are also in the form of a media interview twice,Emphasize safety of soda lime glass bottled sodium bicarbonate injection.(Yin Cong)